Research Papers:

Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma

Da-Xiong Zeng, Chang-Guo Wang, Wei Lei, Jian-An Huang and Jun-Hong Jiang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:66248-66253. https://doi.org/10.18632/oncotarget.19908

Metrics: PDF 1368 views  |   HTML 2327 views  |   ?  


Da-Xiong Zeng1,*, Chang-Guo Wang1,*, Wei Lei1, Jian-An Huang1 and Jun-Hong Jiang1

1Department of Respiratory and Critical Care, The First Affiliated Hospital of Soochow University, Suzhou, China

*These authors have contributed equally to this work

Correspondence to:

Jun-Hong Jiang, email: [email protected]

Keywords: lung cancer, apatinib, adenocarcinoma, VEGFR-2, EGFR wild-type

Received: March 29, 2017     Accepted: June 30, 2017     Published: August 03, 2017


Chemotherapy is the standard treatment of in advanced lung adenocarcinoma patients without driver mutation. However, few drugs could be selected when diseases progressed after second-line treatment. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), apatinib was suggested mainly using in advanced gastric cancer. In this study, we showed the results of apatinib as second-line to fourth-line treatment in EGFR wild-type advanced lung adenocarcinoma patients. 16 EGFR wild-type advanced lung adenocarcinoma patients were administrated apatinib (250-500 mg/d) orally. 3 patients showed partial response and 8 patients showed stable diseases response to apatinib, with a medium progression-free survival (PFS) of 4.4 month (2-10 months). The objective remission rate (ORR) was 18.75%(3/16). The total disease control rate (DCR) was 68.75% (11/16). The main toxicities were hypertension, hand-foot syndrome, proteinuria and thrombocytopenia which were tolerable and manageable. So, apatinib might be an optional choice for post-first-line treatment of EGFR wild-type advanced lung adenocarcinoma patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19908